Mercoledì 18 Ottobre 2023, ore 13
Dipartimento di Medicina e Chirurgia
Edificio Asclepio U8 - Aula 1
DA REMOTO CLICCA QUI PER ACCEDERE A WEBEX
1985: the first haematopoietic stem cell transplant (HSCT) took place and the Pediatric Transplant Center in Monza was born. Since then more than 900 transplants have been performed, mainly in acute leukemia our HSCT Unit, directed today by Adriana Balduzzi.
HSCT can be a curative treatment for children and adolescents with very-high-risk hematological malignancies, refractory to standard or innovative treatment and some non malignant hematological or congenital diseases. Improvements in supportive care and transplant techniques have led to increasing numbers of long-term survivors worldwide.
However, a wide range of adverse late effects and severe sequelae, impact quality of life and result in a shorter life expectancy compared with sex- and age-matched healthy subjects. Every system and organ can be affected, with endocrine issues involving potentially all patients, with youngest patients at the time of HSCT being at higher risk of severe complications, due to their vulnerable developing organs.
Access to life-long care and surveillance are mandatory. Alessandro Cattoni is in charge of our long-term follow-up clinic, which has the aim to prevent, early detect, ameliorate and manage all possible late effects after HSCT, which challenge health care professionals for the need of interdisciplinary interventions and transition to adult services.
We’ll report about endocrine and gonadal impairment, osteonecrosis and iron overload in our cohorts of survivors after HSCT performed during childhood or adolescence.
Adriana Balduzzi works in Monza as Pediatric Transplant Unit Director, within the Fondazione IRCCS San Gerardo dei Tintori. She is a full Professor of Pediatrics within the Milano-Bicocca University, Department of Medicine and Surgery. She is also active member of the Board of the Pediatric Diseases Working Party of the EBMT
Since her graduation she has been working in the field of pediatric hematopoietic transplantation. At the present she is in charge of both academic and company-driven protocols investigating safety and efficacy of innovative manipulated cell products, including CAR-t cells, to manage refractory diseases and tailor minimal residual disease-driven interventions in transplantation for acute lymphoblastic leukemia in children, adolescents and young adults affected with hematological diseases.
Prof. Balduzzi is the principal investigator of the EU FORTEe Project in Monza promoting precision exercise in hemato-oncological patients.
She extensively published on unrelated donor transplantation in pediatrics, and a pivotal article in which a randomization by genetic chance could show the benefit of transplantation over chemotherapy in pediatric patients affected with very high-risk acute lymphoblastic leukemia.
Alessandro Cattoni works as a pediatrician at the Fondazione IRCCS San Gerardo dei Tintori in Monza and he has been is in charge of the Paediatric Endocrinology outpatient clinic of the same Institution since 2019.
Following his graduation, he started to develop a specific interest in the field of long-term endocrine sequelae of childhood cancer survivors. By spending part of his training in a tertiary UK Centre with a historical commitment in the setting of pediatric cancer survivorship (The Royal Marsden Hospital, London), he gathered experience in this field and had the chance of setting a clinical Service specifically dedicated to the detection and treatment of chemo- and radio-induced endocrine late effects in Monza.
He has also designed and implemented the fertility preservation pathway for children, adolescents and young adults with a recently diagnosed onco-hematological disease in the same Institution.
Dr. Cattoni is the principal investigator of several monocentric and multicentric studies in the fields of endocrinology and cancer survivorship.
From an academic perspective, Dr. Cattoni was appointed as a Research Fellow between 2018 and 2019 at the Milan-Bicocca University and subsequently as Type-A fixed type researcher at the same Institution from 2020 onwards.
He is an active member of several study groups of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP) and he is consultant for the Italian Society of Paediatric Onco-Haematology (AIEOP) late effects working party. In addition, he is member of the writing committee for the guidelines about gonadal ovarian insufficiency among childhood cancer survivors for the International Guideline Harmonization Group and for the Late Effects Section
of the FORUM 2 (For Omitting Radiation Under Majority age) international Protocol.